A Phase 3 interventional study of Ticagrelor and Clopidogrel in Peripheral Artery Disease, sponsored by AstraZeneca. Completed at 778 sites in 28 countries. Open to participants aged 50 Years to 130 Years. Per ClinicalTrials.gov, last updated 2017-10-30.
Sponsored by AstraZeneca · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing ticagrelor in Peripheral Arterial Disease — 1 open to participants now, 2 under way, none of them phase 3. Ticagrelor · Peripheral Arterial Disease.
Among the 10 studies testing ticagrelor in Peripheral Arterial Disease, this one has the largest enrollment, is the only one that started in 2012, is one of 3 in phase 3, and was the 1st registered.
1,377 studies on the registry are indexed under Peripheral Arterial Disease; 275 are open to participants now.
Browse Peripheral Arterial Disease studies →1 of the 10 studies testing ticagrelor in Peripheral Arterial Disease is open now, in 1 country. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18+
By country, each count listing its studies:
Ticagrelor: first FDA approval 2011 (BRILINTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 192 Peripheral Arterial Disease studies recruiting now, 138 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.
This study: 50 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 4 · Phase 4 2
First in 2012; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 13,885 is above the median of 70 across 927 interventional studies indexed under Peripheral Arterial Disease.
Median enrollment 58 across the 10 interventional studies. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 10 have an industry lead sponsor. The 7 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
AstraZeneca has 6 studies filed under Peripheral Arterial Disease — fewer than ten, so there is no comparison to draw.
1 of the studies testing ticagrelor in Peripheral Arterial Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07613840Massachusetts General HospitalPersonalizing Thromboprophylaxis for Patients With Peripheral Artery Disease | 2027-04-29 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing ticagrelor in Peripheral Arterial Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the effects of ticagrelor and clopidogrel in patients with Peripheral Artery Disease.
A randomized, double-blind, parallel group, multicentre phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischemic stroke in patients with established Peripheral Artery Disease (EUCLID Examining Use of tiCagreLor In paD)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Ticagrelor 90 mg bd (and Clopidogrel placebo od) taken orally as tablets
Drug: Ticagrelor
Clopidogrel 75 mg od (and Ticagrelor placebo bd) taken orally as tablets
Drug: Clopidogrel
Ticagrelor 90 mg bd (and Clopidogrel placebo od) taken orally as tablets
Also known as: Brilinta/Brilique
Clopidogrel 75 mg od (and Ticagrelor placebo bd) taken orally as tablets
Also known as: Plavix
Composite of Cardiovascular (CV) Death/MI/Ischemic Stroke
Participants with CV death, myocardial infarction (MI) or ischemic stroke. If no event, censoring occurs at the minimum of (primary analysis censoring date (PACD), last endpoint assessment date, non-CV death date)
Time frame: From randomization to PACD, an average of 2.5 years
Composite of CV Death, MI, Ischemic Stroke, and ALI
Participants with CV death, MI, ischemic stroke or acute limb ischemia (ALI). If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date)
Time frame: From randomization to PACD, an average of 2.5 years
CV Death
Participants with CV death. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date)
Time frame: From randomization to PACD, an average of 2.5 years
MI
Participants with MI. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date)
Time frame: From randomization to PACD, an average of 2.5 years
All-cause Mortality
Participants with all-cause death. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date)
Time frame: From randomization to PACD, an average of 2.5 years
Composite of CV Death, MI, and All-cause Stroke (Ischemic or Hemorrhagic)
Participants with CV death, MI or all-cause stroke. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date)
Time frame: From randomization to PACD, an average of 2.5 years
ALI
Participants with ALI. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date)
Time frame: From randomization to PACD, an average of 2.5 years
Lower Extremity Revascularization
Participants with lower extremity revascularization (LER). If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date)
Time frame: From randomization to PACD, an average of 2.5 years
Any Revascularisation (Coronary, Peripheral [Limb, Mesenteric, Renal, Carotid and Other])
Participants with any revascularization. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date)
Time frame: From randomization to PACD, an average of 2.5 years
Net Clinical Benefit (Composite of CV Death/MI/Ischemic Stroke/Fatal Bleeding/Intracranial Bleeding)
Participants with CV death, MI, ischemic stroke, fatal bleeding or intracranial bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date)
Time frame: From randomization to PACD, an average of 2.5 years
Net Clinical Benefit (Composite of All-cause Mortality/MI/Ischemic Stroke/Fatal Bleeding/Intracranial Bleeding)
Participants with all-cause death, MI, ischemic stroke, fatal bleeding or intracranial bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date)
Time frame: From randomization to PACD, an average of 2.5 years
Net Clinical Benefit (Composite of All-cause Mortality/MI/Ischemic Stroke/ALI/Major Amputation/Fatal Bleeding/Intracranial Bleeding)
Participants with all-cause death, MI, ischemic stroke, ALI, major amputation, fatal bleeding or intracranial bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date)
Time frame: From randomization to PACD, an average of 2.5 years
Net Clinical Benefit (Composite of All-cause Mortality/MI/Ischemic Stroke/ALI/Major Amputation/TIMI Major Bleeding)
Participants with all-cause death, MI, ischemic stroke, ALI, major amputation or Thrombolysis in Myocardial Infarction (TIMI) major bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date)
Time frame: From randomization to PACD, an average of 2.5 years
Non-CV Death
Participants with non-CV death. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, CV death)
Time frame: From randomization to PACD, an average of 2.5 years
Changes in Fontaine Stage
Progression of the clinical/symptomatic status of the limb by changes in Fontaine stage. Stage I - Asymptomatic Stage IIa - Intermittent claudication after more than 200 meters of pain free walking Stage IIb - Intermittent claudication after less than 200 meters of walking Stage III - Rest pain Stage IV - Ischemic ulcers or gangrene
Time frame: From randomization to PACD, an average of 2.5 years
Changes in Rutherford Classification
Progression of the clinical/symptomatic status of the limb by changes in Rutherford classification. Category 0 - Asymptomatic Category 1 - Mild claudication Category 2 - Moderate claudication - The distance that delineates mild, moderate and severe claudication is not specified in the Rutherford classification, but is mentioned in the Fontaine classification as 200 meters. Category 3 - Severe claudication Category 4 - Rest pain Category 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Category 6 - Severe ischemic ulcers or frank gangrene
Time frame: From randomization to PACD, an average of 2.5 years
Change in ABI/TBI From Baseline
Change in ankle brachial index (ABI) / toe brachial index (TBI). Ankle brachial index (ABI) is the ratio of blood pressures from the ankle and arm and is used for diagnosing peripheral arterial occlusive disease (PAOD): Normal: 1 to 1.29 Borderline: 0.91 to 0.99 Mild PAOD: 0.71 to 0.90 Medium severe PAOD: 0.41 to 0.7 Severe PAOD: \<0.4 Toe brachial index (TBI) is the ratio between the toe pressure and the higher brachial pressure, used for diagnosing PAOD when the ABI cannot be used: Normal: \>0.7 Mild: 0.5-0.7 Moderate: 0.35-0.5 Moderate-Severe: \<0.35 and toe pressure 40 mmHg Severe: \<0.35 and toe pressure \< 30 mmHg
Time frame: From randomization to PACD, an average of 2.5 years
Any Amputation Caused by PAD
Participants with any amputation caused by peripheral arterial disease (PAD). If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date)
Time frame: From randomization to PACD, an average of 2.5 years
Major Amputation Caused by PAD
Participants with major amputation caused by PAD. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date)
Time frame: From randomization to PACD, an average of 2.5 years
CV-related Hospitalization
Participants with hospitalization associated with CV death, hospitalization due to MI, ischemic stroke, lower extremity revascularization, major amputation due to PAD, transient ischemic attack (TIA), coronary revascularization or unstable angina. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date)
Time frame: From randomization to PACD, an average of 2.5 years
TIMI Major Bleeding Events
Participants with TIMI major bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug)
Time frame: From the date of first dose and up to and including 7 days following the date of last dose of study drug
TIMI Major or Minor Bleeding Events
Participants with TIMI major or minor bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug)
Time frame: From the date of first dose and up to and including 7 days following the date of last dose of study drug
PLATO Major Bleeding Events
Participants with PLATO major bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug)
Time frame: From the date of first dose and up to and including 7 days following the date of last dose of study drug
Premature Permanent Discontinuation of Study Drug Due to Any Bleeding Event
Participants with a permanent discontinuation of study drug due to any bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug)
Time frame: From the date of first dose and up to and including 7 days following the date of last dose of study drug
This study was conducted at 821 centres randomising patients across 28 countries. The first patient was enrolled on 04 December 2012. The last visit of the last patient took place on 26 September 2016. In total, 16237 patients were screened.
| Milestone | Ticagrelor 90 mg bd | Clopidogrel 75 mg od |
|---|---|---|
| Started | 6930 | 6955 |
| Completed | 6807 | 6842 |
| Not completed | 123 | 113 |
| Withdrew: Withdrawal by subject | 123 | 113 |
Participants with CV death, myocardial infarction (MI) or ischemic stroke. If no event, censoring occurs at the minimum of (primary analysis censoring date (PACD), last endpoint assessment date, non-CV death date)
| Participants | Ticagrelor 90 mg bd | Clopidogrel 75 mg od |
|---|---|---|
| Composite of Cardiovascular (CV) Death/MI/Ischemic Stroke | 751 | 740 |
Participants with CV death, MI, ischemic stroke or acute limb ischemia (ALI). If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date)
| Participant | Ticagrelor 90 mg bd | Clopidogrel 75 mg od |
|---|---|---|
| Composite of CV Death, MI, Ischemic Stroke, and ALI | 839 | 833 |
Participants with CV death. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date)
| Participant | Ticagrelor 90 mg bd | Clopidogrel 75 mg od |
|---|---|---|
| CV Death | 363 | 343 |
Participants with MI. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date)
| Participant | Ticagrelor 90 mg bd | Clopidogrel 75 mg od |
|---|---|---|
| MI | 349 | 334 |
Participants with all-cause death. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date)
| Participant | Ticagrelor 90 mg bd | Clopidogrel 75 mg od |
|---|---|---|
| All-cause Mortality | 628 | 635 |
Participants with CV death, MI or all-cause stroke. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date)
| Participant | Ticagrelor 90 mg bd | Clopidogrel 75 mg od |
|---|---|---|
| Composite of CV Death, MI, and All-cause Stroke (Ischemic or Hemorrhagic) | 766 | 759 |
Participants with ALI. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date)
| Participant | Ticagrelor 90 mg bd | Clopidogrel 75 mg od |
|---|---|---|
| ALI | 117 | 115 |
Participants with lower extremity revascularization (LER). If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date)
| Participant | Ticagrelor 90 mg bd | Clopidogrel 75 mg od |
|---|---|---|
| Lower Extremity Revascularization | 846 | 892 |
Participants with any revascularization. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date)
| Participant | Ticagrelor 90 mg bd | Clopidogrel 75 mg od |
|---|---|---|
| Any Revascularisation (Coronary, Peripheral [Limb, Mesenteric, Renal, Carotid and Other]) | 1211 | 1250 |
Participants with CV death, MI, ischemic stroke, fatal bleeding or intracranial bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date)
| Participant | Ticagrelor 90 mg bd | Clopidogrel 75 mg od |
|---|---|---|
| Net Clinical Benefit (Composite of CV Death/MI/Ischemic Stroke/Fatal Bleeding/Intracranial Bleeding) | 789 | 786 |
Participants with all-cause death, MI, ischemic stroke, fatal bleeding or intracranial bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date)
| Participant | Ticagrelor 90 mg bd | Clopidogrel 75 mg od |
|---|---|---|
| Net Clinical Benefit (Composite of All-cause Mortality/MI/Ischemic Stroke/Fatal Bleeding/Intracranial Bleeding) | 983 | 992 |
Participants with all-cause death, MI, ischemic stroke, ALI, major amputation, fatal bleeding or intracranial bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date)
| Participant | Ticagrelor 90 mg bd | Clopidogrel 75 mg od |
|---|---|---|
| Net Clinical Benefit (Composite of All-cause Mortality/MI/Ischemic Stroke/ALI/Major Amputation/Fatal Bleeding/Intracranial Bleeding) | 1119 | 1140 |
Participants with all-cause death, MI, ischemic stroke, ALI, major amputation or Thrombolysis in Myocardial Infarction (TIMI) major bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date)
| Participant | Ticagrelor 90 mg bd | Clopidogrel 75 mg od |
|---|---|---|
| Net Clinical Benefit (Composite of All-cause Mortality/MI/Ischemic Stroke/ALI/Major Amputation/TIMI Major Bleeding) | 1183 | 1199 |
Participants with non-CV death. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, CV death)
| Participant | Ticagrelor 90 mg bd | Clopidogrel 75 mg od |
|---|---|---|
| Non-CV Death | 250 | 272 |
Progression of the clinical/symptomatic status of the limb by changes in Fontaine stage. Stage I - Asymptomatic Stage IIa - Intermittent claudication after more than 200 meters of pain free walking Stage IIb - Intermittent claudication after less than 200 meters of walking Stage III - Rest pain Stage IV - Ischemic ulcers or gangrene
| Participant | Ticagrelor - Stage I | Ticagrelor - Stage IIa | Ticagrelor - Stage IIb | Ticagrelor - Stage III | Ticagrelor - Stage IV | Clopidogrel - Stage I | Clopidogrel - Stage IIa | Clopidogrel - Stage IIb | Clopidogrel - Stage III | Clopidogrel - Stage IV |
|---|---|---|---|---|---|---|---|---|---|---|
| Stage I - End of treatment | 775 | 683 | 171 | 15 | 26 | 743 | 723 | 198 | 33 | 19 |
| Stage IIa - End of treatment | 227 | 1948 | 560 | 41 | 28 | 230 | 1956 | 557 | 33 | 21 |
| Stage IIb - End of treatment | 45 | 269 | 469 | 39 | 19 | 56 | 311 | 450 | 38 | 15 |
| Stage III - End of treatment | 7 | 24 | 12 | 31 | 7 | 9 | 15 | 23 | 23 | 12 |
| Stage IV - End of treatment | 7 | 7 | 5 | 1 | 13 | 4 | 7 | 10 | 5 | 13 |
| Missing - End of treatment | 248 | 743 | 403 | 59 | 47 | 250 | 724 | 370 | 60 | 45 |
Progression of the clinical/symptomatic status of the limb by changes in Rutherford classification. Category 0 - Asymptomatic Category 1 - Mild claudication Category 2 - Moderate claudication - The distance that delineates mild, moderate and severe claudication is not specified in the Rutherford classification, but is mentioned in the Fontaine classification as 200 meters. Category 3 - Severe claudication Category 4 - Rest pain Category 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Category 6 - Severe ischemic ulcers or frank gangrene
| Participant | Ticagrelor - Cat 0 | Ticagrelor - Stage II | Ticagrelor - Cat 3 | Ticagrelor - Cat 4 | Ticagrelor - Cat 5 | Ticagrelor - Cat 6 | Clopidogrel - Cat 0 | Clopidogrel - Cat 1/2 | Clopidogrel - Cat 3 | Clopidogrel - Cat 4 | Clopidogrel - Cat 5 | Clopidogrel - Cat 6 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Category 0 - End of treatment | 775 | 683 | 171 | 15 | 23 | 3 | 743 | 723 | 198 | 33 | 13 | 6 |
| Category 1/2 - End of treatment | 227 | 1948 | 560 | 41 | 23 | 5 | 230 | 1956 | 557 | 33 | 18 | 3 |
| Category 3 - End of treatment | 45 | 269 | 469 | 39 | 13 | 6 | 56 | 311 | 450 | 38 | 12 | 3 |
| Category 4 - End of treatment | 7 | 24 | 12 | 31 | 4 | 3 | 9 | 15 | 23 | 23 | 11 | 1 |
| Category 5 - End of treatment | 5 | 4 | 3 | 1 | 11 | 0 | 2 | 6 | 6 | 4 | 12 | 1 |
| Category 6 - End of treatment | 2 | 3 | 2 | 0 | 0 | 2 | 2 | 1 | 4 | 1 | 0 | 0 |
| Missing - End of treatment | 248 | 743 | 403 | 59 | 33 | 14 | 250 | 724 | 370 | 60 | 34 | 11 |
Change in ankle brachial index (ABI) / toe brachial index (TBI). Ankle brachial index (ABI) is the ratio of blood pressures from the ankle and arm and is used for diagnosing peripheral arterial occlusive disease (PAOD): Normal: 1 to 1.29 Borderline: 0.91 to 0.99 Mild PAOD: 0.71 to 0.90 Medium severe PAOD: 0.41 to 0.7 Severe PAOD: \<0.4 Toe brachial index (TBI) is the ratio between the toe pressure and the higher brachial pressure, used for diagnosing PAOD when the ABI cannot be used: Normal: \>0.7 Mild: 0.5-0.7 Moderate: 0.35-0.5 Moderate-Severe: \<0.35 and toe pressure 40 mmHg Severe: \<0.35 and toe pressure \< 30 mmHg
| Change in ABI/TBI | Ticagrelor 90 mg bd | Clopidogrel 75 mg od |
|---|---|---|
| ABI - 6 months N = 6184(Tica), 6319(Clopi) | 0.016 ± 0.136 | 0.011 ± 0.134 |
| ABI - End of treatment N = 4951(Tica), 5073(Clopi) | 0.022 ± 0.167 | 0.016 ± 0.167 |
| TBI - 6 months N = 55(Tica), 48(Clopi) | 0.050 ± 0.132 | 0.036 ± 0.137 |
| TBI - End of treatment N = 36(Tica), 21(Clopi) | 0.059 ± 0.115 | -0.065 ± 0.304 |
Participants with any amputation caused by peripheral arterial disease (PAD). If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date)
| Participant | Ticagrelor 90 mg bd | Clopidogrel 75 mg od |
|---|---|---|
| Any Amputation Caused by PAD | 179 | 208 |
Participants with major amputation caused by PAD. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date)
| Participant | Ticagrelor 90 mg bd | Clopidogrel 75 mg od |
|---|---|---|
| Major Amputation Caused by PAD | 100 | 116 |
Participants with hospitalization associated with CV death, hospitalization due to MI, ischemic stroke, lower extremity revascularization, major amputation due to PAD, transient ischemic attack (TIA), coronary revascularization or unstable angina. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date)
| Participant | Ticagrelor 90 mg bd | Clopidogrel 75 mg od |
|---|---|---|
| CV-related Hospitalization | 1312 | 1314 |
Participants with TIMI major bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug)
| Participant | Ticagrelor 90 mg bd | Clopidogrel 75 mg od |
|---|---|---|
| TIMI Major Bleeding Events | 113 | 109 |
Participants with TIMI major or minor bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug)
| Participant | Ticagrelor 90 mg bd | Clopidogrel 75 mg od |
|---|---|---|
| TIMI Major or Minor Bleeding Events | 193 | 175 |
Participants with PLATO major bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug)
| Participant | Ticagrelor 90 mg bd | Clopidogrel 75 mg od |
|---|---|---|
| PLATO Major Bleeding Events | 206 | 188 |
Participants with a permanent discontinuation of study drug due to any bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug)
| Participant | Ticagrelor 90 mg bd | Clopidogrel 75 mg od |
|---|---|---|
| Premature Permanent Discontinuation of Study Drug Due to Any Bleeding Event | 168 | 112 |
Collected over On or after the date of first dose and up to and including 7 days following the date of last dose of study medication. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Clopidogrel 75mg od | — | 1,788/6,932 (25.8%) | 989/6,932 (14.3%) |
| Ticagrelor 90mg bd | — | 1,716/6,910 (24.8%) | 1,682/6,910 (24.3%) |
| Event | Clopidogrel 75mg od | Ticagrelor 90mg bd |
|---|---|---|
| PneumoniaInfections and infestations | 164/6932 | 137/6910 |
| Cardiac failure congestiveCardiac disorders | 88/6932 | 68/6910 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 71/6932 | 87/6910 |
| Atrial fibrillationCardiac disorders | 67/6932 | 69/6910 |
| Carotid artery stenosisNervous system disorders | 60/6932 | 56/6910 |
| Acute kidney injuryRenal and urinary disorders | 32/6932 | 48/6910 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 41/6932 | 40/6910 |
| Urinary tract infectionInfections and infestations | 40/6932 | 32/6910 |
| AnaemiaBlood and lymphatic system disorders | 38/6932 | 39/6910 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 38/6932 | 34/6910 |
| Event | Clopidogrel 75mg od | Ticagrelor 90mg bd |
|---|---|---|
| HaemorrhageVascular disorders | 787/6932 | 997/6910 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 264/6932 | 817/6910 |
| Age, Continuous(Years) | Ticagrelor 90mg bd | Clopidogrel 75mg od | Total |
|---|---|---|---|
| Age | 66.6 ± 8.4 | 66.5 ± 8.5 | 66.6 ± 8.4 |
| Age, Customized(Participants) | Ticagrelor 90mg bd | Clopidogrel 75mg od | Total |
|---|---|---|---|
| <65 years | 2900 | 2985 | 5885 |
| Between 65 and 75 years | 2925 | 2850 | 5775 |
| >75 years | 1105 | 1120 | 2225 |
| Sex: Female, Male(Participants) | Ticagrelor 90mg bd | Clopidogrel 75mg od | Total |
|---|---|---|---|
| Female | 1908 | 1980 | 3888 |
| Male | 5022 | 4975 | 9997 |
| Race/Ethnicity, Customized(Participants) | Ticagrelor 90mg bd | Clopidogrel 75mg od | Total |
|---|---|---|---|
| Hispanic Or Latino | 1046 | 1067 | 2113 |
| Not Hispanic Or Latino | 5884 | 5888 | 11772 |
| Race/Ethnicity, Customized(Participants) | Ticagrelor 90mg bd | Clopidogrel 75mg od | Total |
|---|---|---|---|
| American Indian Or Alaska Native | 63 | 62 | 125 |
| Asian | 824 | 810 | 1634 |
| Black Or African American | 280 | 289 | 569 |
| Native Hawaiian Or Other Pacific Islander | 2 | 3 | 5 |
| Other | 110 | 132 | 242 |
| White | 5651 | 5659 | 11310 |
Showing the first 100 of 778 sites across 28 countries. Choose a country and city above to see the rest.
Ran from Dec 2012 to primary completion in Sep 2016, 45 months.
Results were first posted in Oct 2017, 1 year 1 month after primary completion.
Of 26 phase 3 interventional studies under Peripheral Arterial Disease, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 58. This study's 45 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ticagrelor